Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 66 of 116

  1. Part 1: VP-315 3 Day Dosing/Week

    Verrica Pharmaceuticals

    Basal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  2. Patritumab deruxtecan

    Daiichi Sankyo

    Locally Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  3. Patritumab deruxtecan

    Daiichi Sankyo

    Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  4. Patupilone

    Novartis Pharmaceuticals

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  5. Paxalisib

    KAZIA THERAPEUTICS LTD

    Childhood Cancer

    phase 2 small molecule active

    1 trial

  6. Pedmark® STS

    FENNEC PHARMACEUTICALS INC.

    Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  7. Pegvorhyaluronidase alfa

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  8. Pegylated Irinotecan

    Nektar Therapeutics UK Limited

    Stage IV Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule completed

    1 trial

  9. Pegylated Irinotecan

    Nektar Therapeutics UK Limited

    Recurrent Small Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  10. Pelareorep

    ONCOLYTICS BIOTECH INC

    Anatomic Stage IV Breast Cancer AJCC v8

    phase 2 mab active

    1 trial

  11. Pelareorep

    ONCOLYTICS BIOTECH INC

    Anal Cancer Metastatic

    phase 2 small molecule active

    1 trial

  12. Pemazyre 4.5 mg tablets

    Ningbo Cancer Hospital

    Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rearrangement or activating mutation, outside of the approved indications for any selective FGFR inhibitor in France

    phase 2 small molecule active

    1 trial

  13. Pemazyre 4.5 mg tablets

    The George Institute

    locally advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements

    phase 2 small molecule active

    1 trial

  14. Pembrolizumab

    ALX ONCOLOGY HOLDINGS INC

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  15. Pembrolizumab

    Syndax Pharmaceuticals

    Metastatic Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  16. Pembrolizumab

    Genmab A/S

    Advanced Endometrial Cancer

    phase 2 mab terminated

    1 trial

  17. Pembrolizumab

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  18. Pembrolizumab

    United Therapeutics Europe Ltd

    Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  19. Pembrolizumab

    United Therapeutics Europe Ltd

    Metastatic Small Intestinal Adenocarcinoma

    phase 2 mab active

    1 trial

  20. Pembrolizumab

    United Therapeutics Europe Ltd

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  21. Pembrolizumab

    United Therapeutics Europe Ltd

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  22. Pembrolizumab

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 2 mab terminated

    1 trial

  23. Pembrolizumab

    Incyte

    Lung Cancer

    phase 2 small molecule completed

    2 trials

  24. Pembrolizumab

    Syndax Pharmaceuticals

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  25. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Melanoma

    phase 2 mab completed

    1 trial

  26. Pembrolizumab

    IO Biotech

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  27. Pembrolizumab

    Karyopharm Therapeutics Inc

    Advanced Urothelial Carcinoma

    phase 2 mab terminated

    1 trial

  28. Pembrolizumab

    Bicara Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  29. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Advanced Non-Small Cell Lung Cancer

    phase 2 mab completed

    1 trial

  30. Pembrolizumab

    Inhibrx Biosciences

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  31. Pembrolizumab (+) Berahyaluronidase alfa

    Merck KGaA, Darmstadt, Germany

    Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  32. Pembrolizumab (200mg IV for 30 minutes

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  33. Pembrolizumab (KEYTRUDA®) and PDS0101

    PDS Biotechnology Corp

    Metastatic Head and Neck Cancer

    phase 2 other completed

    1 trial

  34. Pembrolizumab 200 mg

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  35. Pembrolizumab 200 mg

    Merck KGaA, Darmstadt, Germany

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 mab active

    1 trial

  36. Pembrolizumab 200 mg IV infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stage IIIB(N2) Non-small Cell Lung Cancer

    phase 2 mab active

    1 trial

  37. Pembrolizumab Injection

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  38. Pembrolizumab plus denosumab

    Zealand Pharma A/S

    Renal Cell Carcinoma, Clear Cell

    phase 2 small molecule active

    1 trial

  39. Pembrolizumab/Vibostolimab coformulation

    Merck KGaA, Darmstadt, Germany

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab completed

    1 trial

  40. Pemebit

    Hospital Authority, Hong Kong

    Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  41. Pemetrexe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  42. Pemetrexed

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

  43. Pemetrexed

    Mereo BioPharma Group plc

    Nonsquamous Nonsmall Cell Neoplasm of Lung

    phase 2 small molecule completed

    1 trial

  44. Pemetrexed

    Samsung Bioepis NL B.V.

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  45. Pemetrexed Ever Pharma /ml concentrato per so...

    Fondazione Telethon ETS

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  46. Pemetrexed and Reolysin (and safety run-in)

    ONCOLYTICS BIOTECH INC

    Non Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  47. Pentasa Sachet depotgranulat for Lynch syndrome, which is increa…

    The George Institute

    Lynch syndrome, which is increasing the risk of developing colorectal cancer

    phase 2 small molecule active

    1 trial

  48. Pevonedistat

    Takeda

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule completed

    2 trials

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.